Welcome to our dedicated page for uniQure N.V. SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on uniQure N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into uniQure N.V.'s regulatory disclosures and financial reporting.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported an automatic tax-related share sale. On March 2, 2026, he sold 12,532 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic sale instructions in the RSU agreement, meaning the sale was not a discretionary trade. Following the transaction, he directly owned 198,981 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported an automatic sale of 8,578 ordinary shares. The shares were sold on March 2, 2026 in open-market transactions at a weighted average price of $9.95 per share.
According to the disclosure, the sale occurred upon the vesting of restricted share units and was made solely to cover estimated withholding taxes under automatic sale instructions, meaning it was not a discretionary trade by Potts. Following these transactions, she directly owned 106,495 ordinary shares of uniQure N.V.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an automatic sale of 1,660 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and were not a discretionary trade. After this transaction, Abi-Saab直接 owns 148,777 ordinary shares. The sale price reflected multiple trades between $9.67 and $10.25.
uniQure N.V. filed a Form 144 reporting a proposed sale of 34,437 ordinary shares. The filing lists Citigroup Global Markets as the broker and identifies 03/02/2026 as the filing date. The notice also discloses 49,999 restricted stock units vesting on 03/02/2026 as compensation. Separately, the filing records a sale by Matthew Kapusta of 12,378 ordinary shares on 02/25/2026 for $295,306.90.
uniQure NV submitted a Form 144 notice relating to ordinary shares dated 03/02/2026. The filing lists 16,499 restricted stock units vesting on 03/02/2026 and records a sale of 6,217 ordinary shares by Klemt Christian on 02/25/2026
uniQure N.V. filed its Annual Report describing a broad gene therapy pipeline and major 2025–2026 developments. The lead Huntington’s disease program AMT‑130 showed favorable 36‑month high‑dose data and received FDA Breakthrough, RMAT, Orphan Drug and Fast Track designations.
However, after pre‑BLA and Type A meetings, the FDA said current Phase I/II data using external controls are unlikely to provide primary evidence for approval and strongly recommended a prospective, randomized, sham‑surgery‑controlled Phase III study. Early‑stage programs saw mixed outcomes, with promising AMT‑260 epilepsy data but safety‑driven pauses in the SOD1‑ALS trial (AMT‑162) and higher‑dose Fabry cohorts (AMT‑191).
To fund these efforts, uniQure completed two follow‑on equity offerings in 2025 raising net proceeds of about $404.2 million and entered a new $175.0 million term loan facility with Hercules, providing substantial capital but adding debt obligations through 2030.
uniQure N.V. reported 2025 results and a key regulatory update on its Huntington’s disease program AMT-130. The company ended December 31, 2025 with $622.5 million in cash, cash equivalents and current investment securities, up from $367.5 million a year earlier, largely after raising about $404.2 million through public offerings of ordinary shares and pre-funded warrants.
Full-year 2025 revenue was $16.1 million, down from $27.1 million in 2024, mainly due to lower collaboration and contract manufacturing revenue, partly offset by higher license revenue. The net loss narrowed to $199.0 million, or $3.46 per share, compared with a $239.6 million loss, or $4.92 per share, in 2024. Shareholders’ equity improved to $198.9 million from a deficit of $6.8 million. Management expects the year-end cash position to fund operations into the second half of 2029.
On AMT-130, the U.S. FDA told uniQure that Phase I/II data using an external control are not sufficient as primary evidence of effectiveness to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. uniQure plans to seek a Type B FDA meeting in the second quarter of 2026 to discuss Phase III design. The company also highlighted progress in other gene therapy programs, including AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease, and completed enrollment of the first AMT-260 Phase I/IIa cohort.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an open-market sale of 12,378 ordinary shares of the company at a weighted average price of $23.86 per share. The shares were sold automatically upon the vesting of restricted share units solely to cover estimated withholding taxes, under pre-set sale instructions, and not as a discretionary trade. After this transaction, Kapusta directly held 639,076 ordinary shares of uniQure.
uniQure N.V. Chief Financial Officer Christian Klemt reported an open-market sale of 6,217 ordinary shares of the company. The shares were sold at a weighted average price of $23.86 per share and were linked to the vesting of restricted share units.
According to the disclosure, the shares were sold solely to cover estimated withholding taxes under automatic sale instructions in the relevant restricted share unit agreement, meaning the transaction was not a discretionary trade by the executive. After this tax-related sale, Klemt still directly owns 211,513 ordinary shares.